专业监测看板

Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus

药物 / 成分：KP104

登记的停止原因（原文）：Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns

Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy

药物 / 成分：Zanzalintinib

登记的停止原因（原文）：Funder withdrew

Efficacy of Oxfendazole in the Treatment of Trichuris Trichiura Infection in Adults

药物 / 成分：Oxfendazole、Albendazole

登记的停止原因（原文）：Study cancelled prior to initiation as the Oxfendazole Development Group is collaborating on a similar study being conducted by AB Prisma, NCT4713787

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

药物 / 成分：Emicizumab、FEIBA、rFVIIa

登记的停止原因（原文）：The study was withdrawn because the pharmaceutical sponsor withdrew support for the study. No participants were enrolled before termination.

Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP)

药物 / 成分：Ketamine、SmartSleep EEG recording headband

登记的停止原因（原文）：Budgeting/funding

Phenobarbital for Agitated Delirium

药物 / 成分：Phenobarbital、Conventional therapy group

登记的停止原因（原文）：Not approved by IRB

Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp

药物 / 成分：Dexamethasone

登记的停止原因（原文）：Lack of funding

Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19

药物 / 成分：Baricitinib、Placebo

登记的停止原因（原文）：The study was planned during COVID-19 outbreak to assess Baricitinib in Patients With Moderate and Severe COVID-19. The study could not be started due to many obstacle which was raised because of Pandemic. The study is no more relevant.

A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis

药物 / 成分：Coagadex(R)

登记的停止原因（原文）：Study was discontinued for non-safety reasons and the rapidly evolving treatment landscape for AL amyloidosis.

Intervention of Engineered Immune Effector T Cells Against Lung Cancer

药物 / 成分：LC-CTLs

登记的停止原因（原文）：combine with NCT03356808

Incretin Hormones in Type 1 Diabetes Mellitus;Effect of Metformin Treatment

药物 / 成分：Metformin、Placebo

登记的停止原因（原文）：It was not conducted due to the emergency restrictive measures implemented during the COVID-19 pandemic, which made it impossible to carry out the patient visits required by the study protocol.

Botox Injections in Non-Cranial Nerve VII Innervated Muscles for Facial Synkinesis

药物 / 成分：Botulinum Toxin Type A Injection [Botox]

登记的停止原因（原文）：Unable to secure funding for TMJ and masseter Botox.

Creating Linked Inpatient CGM for Kids

登记的停止原因（原文）：Funding was not secured in time to start the study.

Evaluation of Image Quality and Safety of the MyVeo Surgical Visualization Headset During Standard Neurosurgical and Reconstructive Procedures Using Compatible Microscopes.

药物 / 成分：MyVeo is an all-in-one surgical visualization headset used with compatible surgical microscopes and other medical imaging systems in the area of neurosurgery, ENT, spine, plastic and reconstructive su

登记的停止原因（原文）：sufficient existing clinical evidence

Clinical Study of DA-002 and DA-005 as a Treatment for Hair Loss

药物 / 成分：DA-005、Topical minoxidil 5%、DA-002、Placebo Oral Tablet

登记的停止原因（原文）：Sponsor change of formulation

Linperlisib in the Treatment of aPRCA

药物 / 成分：Linperlisib

登记的停止原因（原文）：The manufacturing enterprise has stopped the supply of drugs

Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)

药物 / 成分：CV09070101 mRNA vaccine (CVHNLC) 50 µg、CV09070101 mRNA vaccine (CVHNLC) 100 µg、CV09070101 mRNA vaccine (CVHNLC) 200 µg、CV09070101 mRNA vaccine (CVHNLC) 400 µg

登记的停止原因（原文）：In accordance with 21 CFR 312.38, CureVac is herewith withdrawing IND No. 031346 for CV09070101 (referred to as CVHNLC) for the indication of squamous Non-Small-Cell Lung Cancer (sqNSCLC), following the strategic decision to not pursue the CVHNL

Pharmacokinetic Study of DA-020

药物 / 成分：DA-020 (0.1%)、DA-020 (0.2%)、DA-020 (0.5%)

登记的停止原因（原文）：Change of protocol moved to new study

Linear Asymmetric rTMS in Adolescent Treatment-Resistant Depression: Treatment Durations From Ten Days to One Day

药物 / 成分：Linear Asymmetric rTMS System

登记的停止原因（原文）：Due to a strategic decision by the sponsor, the study has been relocated to a different site, necessitating the withdrawal of this specific registration.

xPedite: A Study to Expedite DIPG and DMG Research

登记的停止原因（原文）：Protocol termination